ClinicalTrials.gg
TerminatedNCT02594163Updated Oct 16, 2018Results posted

Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma

A Phase 2 interventional study of Brentuximab Vedotin and Rituximab in Diffuse Large B-cell Lymphoma Refractory and Follicular B-cell Non-Hodgkin's Lymphoma, sponsored by Seagen Inc.. Terminated at 50 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-16.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision based on portfolio prioritization

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Lymphoma, Large B-Cell, Diffuse by Pfizer — none open to participants now, 1 under way, 1 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Pfizer.

Enrollment
20th of 25
25 · median 58
Started
2015
with 2 others
Phase 2
9 of 25
none open now
Registered
13th of 25
by date

Among the 25 studies in Lymphoma, Large B-Cell, Diffuse by Pfizer, this one is the 20th largest by enrollment, is one of 3 that started in 2015, is one of 9 in phase 2, and was the 13th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

None of the 25 studies in Lymphoma, Large B-Cell, Diffuse by Pfizer is open now. The open studies under Lymphoma, Large B-Cell, Diffuse, anywhere →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 25 studies in Lymphoma, Large B-Cell, Diffuse by Pfizer as a file.
02

Study summary

This is a randomized, open-label, multicenter, Phase 2 clinical trial designed to evaluate the efficacy and safety of brentuximab vedotin in combination with rituximab and bendamustine for the treatment of patients with relapsed or refractory CD30-positive diffuse large B-cell lymphoma (DLBCL) after failure of second-line salvage therapy or as second-line treatment in patients ineligible for autologous stem cell transplant (ASCT).

Read the detailed description

Patients will be randomized in a 1:1 manner to receive rituximab plus bendamustine with or without brentuximab vedotin. Patients who respond to combination treatment containing brentuximab vedotin and do not experience excessive toxicity may receive additional single-agent brentuximab vedotin following combination treatment, for up to an additional 10 cycles (up to 16 total cycles of treatment).

03

Conditions studied

  • Diffuse Large B-cell Lymphoma Refractory
  • Follicular B-cell Non-Hodgkin's Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with confirmed CD30-positive DLBCL or grade 3b follicular non-Hodgkin lymphoma (NHL).
  2. Patients must have disease following:

    1. or greater salvage systemic therapy, or
    2. frontline cytotoxic systemic therapy, for patients who are ineligible for stem cell transplant (SCT).
  3. Age 18 years and older.
  4. Fluorodeoxyglucose (FDG)-avid disease by positron emission tomography (PET).
  5. An (ECOG) performance status score of 0-2.
  6. Acceptable blood test results.
  7. Females of must have a negative pregnancy test result within 7 days prior to the first dose of study drug.
  8. Females of childbearing potential and males who have partners of childbearing potential must agree to use an effective method during the study and for 6 months following the last dose of brentuximab vedotin or 12 months following the last dose of rituximab, whichever is later.
  9. Patients must provide written .

Exclusion criteria

Exclusion Criteria:

  1. History of another invasive that has not been in remission for at least 1 year. (Exceptions are nonmelanoma skin cancer, curatively treated localized prostate cancer, ductal carcinoma, and cervical carcinoma or a squamous intraepithelial lesion on PAP smear).
  2. History of progressive multifocal leukoencephalopathy (PML).
  3. Cerebral/meningeal disease related to the underlying malignancy, unless definitively treated.
  4. Viral, bacterial, or fungal infection within 2 weeks prior to the first dose of treatment.
  5. Chemotherapy, radiotherapy, biologics, and/or other antitumor treatment with immunotherapy that is not completed 4 weeks prior to first dose of study drug.
  6. Females who are pregnant or breastfeeding.
  7. Known allergy to any study drug or ingredient contained in the drug formulation of any of the study drugs.
  8. Known to be positive for . Known to have active infection or on antiviral therapy for hepatitis C within the last 6 months.
  9. Known to be positive for (HIV).
  10. Patients with previous stem cell transplant.
  11. Previous treatment with brentuximab vedotin or bendamustine.
  12. Intolerable toxicity to prior rituximab therapy.
  13. Current therapy with other agents.
  14. Lung disease unrelated to underlying malignancy.
  15. History of a stroke or , unstable angina, myocardial infarction, or cardiac symptoms within 6 months prior to the first dose of treatment.
  16. Congestive heart failure.
  17. Significant peripheral sensory or motor neuropathy at the start of the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Brentuximab Vedotin

    Subjects randomized to the brentuximab vedotin arm will receive IV infusions of brentuximab vedotin followed by bendamustine on day 1, and rituximab followed by bendamustine on day 2 of each 21 day cycle.

    Drug: Brentuximab Vedotin · Drug: Rituximab · Drug: Bendamustine

  • Active comparator
    Rituximab,Bendamustine control

    Subjects randomized to the control arm will receive IV infusions of rituximab on day 1 or day 2 and bendamustine on both days 1 and 2 of each 21 day cycle.

    Drug: Rituximab · Drug: Bendamustine

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the percentage of patients who achieve a Complete Response (CR) (including Complete Metabolic Response (CMR)) or Partial Response (PR) (including Partial Metabolic Response (PMR)) as best response to combination therapy on study

    Time frame: Approximately 1 year

Secondary outcomes

  1. Progression-free Survival (PFS)

    PFS is defined as the time from randomization to disease progression/relapse, receipt of subsequent lymphoma chemotherapy other than the components of the study treatment regimen, or death from any cause, whichever occurs first.

    Time frame: Up to 11.8 months

  2. Complete Remission (CR) Rate

    CRR is the proportion of patients who achieve CR (including Complete Metabolic Response (CMR)) as best response to combination therapy on study.

    Time frame: Approximately 1 year

  3. Duration of Response (DOR)

    DOR is defined as the time from first observation of response to disease progression/relapse, receipt of subsequent lymphoma chemotherapy other than the components of the study treatment regimen, or death from any cause, whichever occurs first.

    Time frame: Up to 10.5 months

  4. Overall Survival (OS)

    OS is defined as the time randomization to death from any cause

    Time frame: Up to 1.5 years

  5. Number and Severity of Adverse Events (AEs)

    All AEs are included in the summaries, unless treatment-emergent is specified.

    Time frame: Approximately 1 year

07

Results

Posted Oct 16, 2018

Participant flow

Treatment Period
Participant flow — Treatment Period
MilestoneRituximab, Bendamustine ControlBrentuximab Vedotin Plus Rituximab Plus Bendamustine
Started1213
Completed51
Not completed712
Withdrew: Progressive disease23
Withdrew: Adverse event15
Withdrew: Physician decision13
Withdrew: Study termination by sponsor21
Withdrew: Other, non-ae10
Follow-up Period
Participant flow — Follow-up Period
MilestoneRituximab, Bendamustine ControlBrentuximab Vedotin Plus Rituximab Plus Bendamustine
Started1213
Completed11
Not completed1112
Withdrew: Withdrawal by subject01
Withdrew: Study termination by sponsor64
Withdrew: Lost to follow-up10
Withdrew: Death25
Withdrew: Adverse event01
Withdrew: Progressive disease20
Withdrew: Physician decision01

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR is defined as the percentage of patients who achieve a Complete Response (CR) (including Complete Metabolic Response (CMR)) or Partial Response (PR) (including Partial Metabolic Response (PMR)) as best response to combination therapy on study

Time frame:
Approximately 1 year
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsRituximab, Bendamustine ControlBrentuximab Vedotin Plus Rituximab Plus Bendamustine
Objective Response Rate (ORR)91.7 (61.5 to 99.8)61.5 (31.6 to 86.1)
SecondaryProgression-free Survival (PFS)

PFS is defined as the time from randomization to disease progression/relapse, receipt of subsequent lymphoma chemotherapy other than the components of the study treatment regimen, or death from any cause, whichever occurs first.

Time frame:
Up to 11.8 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsRituximab, Bendamustine ControlBrentuximab Vedotin Plus Rituximab Plus Bendamustine
Progression-free Survival (PFS)4.9 (1.6 to 11.8)3.7 (0.8 to 11.5)
SecondaryComplete Remission (CR) Rate

CRR is the proportion of patients who achieve CR (including Complete Metabolic Response (CMR)) as best response to combination therapy on study.

Time frame:
Approximately 1 year
Reported as:
Count of participants · Participants
Complete Remission (CR) Rate
ParticipantsRituximab, Bendamustine ControlBrentuximab Vedotin Plus Rituximab Plus Bendamustine
Complete Remission (CR) Rate87
SecondaryDuration of Response (DOR)

DOR is defined as the time from first observation of response to disease progression/relapse, receipt of subsequent lymphoma chemotherapy other than the components of the study treatment regimen, or death from any cause, whichever occurs first.

Time frame:
Up to 10.5 months
Reported as:
Median · months
Duration of Response (DOR)
monthsRituximab, Bendamustine ControlBrentuximab Vedotin Plus Rituximab Plus Bendamustine
Duration of Response (DOR)3.7 (0.0 to 10.5)4.1 (0.0 to 10.1)
SecondaryOverall Survival (OS)

OS is defined as the time randomization to death from any cause

Time frame:
Up to 1.5 years
Reported as:
Median · months
Overall Survival (OS)
monthsRituximab, Bendamustine ControlBrentuximab Vedotin Plus Rituximab Plus Bendamustine
Overall Survival (OS)14.3 (3.9 to 18)6.5 (1.9 to 11.9)
SecondaryNumber and Severity of Adverse Events (AEs)

All AEs are included in the summaries, unless treatment-emergent is specified.

Time frame:
Approximately 1 year
Reported as:
Count of participants · Participants
Number and Severity of Adverse Events (AEs)
ParticipantsRituximab, Bendamustine ControlBrentuximab Vedotin Plus Rituximab Plus Bendamustine
Treatment-Emergent Adverse Event1113
Treatment-Related Adverse Event1013
Brentuximab Vedotin-Related Adverse Event011
Rituximab-Related Adverse Event610
Bendamustine-Related Adverse Event1013
Adverse Event with Outcome of Death01
Serious Adverse Event38
Treatment-Related Serious Adverse Event33
Adverse Event Leading to Dose Delay30
Adverse Event Leading to Treatment Discontinuation15
Grade 3-5 Treatment-Emergent Adverse Event411

Adverse events

Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab, Bendamustine Control2/12 (16.7%)3/12 (25%)11/12 (91.7%)
Brentuximab Vedotin Plus Rituximab Plus Bendamustine5/13 (38.5%)8/13 (61.5%)13/13 (100%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventRituximab, Bendamustine ControlBrentuximab Vedotin Plus Rituximab Plus Bendamustine
SepsisInfections and infestations0/122/13
Febrile neutropeniaBlood and lymphatic system disorders1/120/13
PyrexiaGeneral disorders1/121/13
General physical health deteriorationGeneral disorders1/120/13
Transient ischaemic attackNervous system disorders1/120/13
InfectionInfections and infestations0/121/13
Kidney infectionInfections and infestations0/121/13
LymphangitisInfections and infestations0/121/13
PneumoniaInfections and infestations0/121/13
Pneumonia viralInfections and infestations0/121/13
Most frequent other events
Showing 10 of 88
Most frequent other events
EventRituximab, Bendamustine ControlBrentuximab Vedotin Plus Rituximab Plus Bendamustine
DiarrhoeaGastrointestinal disorders2/126/13
NauseaGastrointestinal disorders3/125/13
VomitingGastrointestinal disorders1/125/13
Abdominal painGastrointestinal disorders0/124/13
PyrexiaGeneral disorders1/124/13
HypokalaemiaMetabolism and nutrition disorders0/124/13
AnaemiaBlood and lymphatic system disorders3/122/13
NeutropeniaBlood and lymphatic system disorders3/121/13
AstheniaGeneral disorders2/123/13
FatigueGeneral disorders2/123/13

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Rituximab, Bendamustine ControlBrentuximab Vedotin Plus Rituximab Plus BendamustineTotal
<=18 years000
Between 18 and 65 years6410
>=65 years6915
Age, Continuous
Age, Continuous(years)Rituximab, Bendamustine ControlBrentuximab Vedotin Plus Rituximab Plus BendamustineTotal
Median64.5 (47 to 85)68.0 (40 to 79)68.0 (40 to 85)
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab, Bendamustine ControlBrentuximab Vedotin Plus Rituximab Plus BendamustineTotal
Female8614
Male4711
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Rituximab, Bendamustine ControlBrentuximab Vedotin Plus Rituximab Plus BendamustineTotal
Hispanic or Latino213
Not Hispanic or Latino71017
Unknown or Not Reported325
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rituximab, Bendamustine ControlBrentuximab Vedotin Plus Rituximab Plus BendamustineTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White91120
More than one race000
Unknown or Not Reported325
Region of Enrollment
Region of Enrollment(participants)Rituximab, Bendamustine ControlBrentuximab Vedotin Plus Rituximab Plus BendamustineTotal
United States235
Czechia101
Poland101
Italy347
United Kingdom145
France426
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Rituximab, Bendamustine ControlBrentuximab Vedotin Plus Rituximab Plus BendamustineTotal
0: Normal Activity7613
1: Symptoms but ambulatory549
2: In bed less than 50% of the time033
08

Study locations

50 sites
  • City of Hope
    Duarte, California 91010, United States
  • Sansum Clinic - West Pueblo
    Santa Barbara, California 93105, United States
  • Good Samaritan Hospital
    Torrance, California 90501, United States
  • The Oncology Institute of Hope and Innovation
    Whittier, California 90603, United States
  • Rocky Mountain Cancer Center
    Aurora, Colorado 80012, United States
  • Kaiser Permanente Oncology
    Lonetree, Colorado 80124, United States
  • Illinois Cancer Specialists
    Niles, Illinois 60714, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40202, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Saint Louis University Cancer Center
    Saint Louis, Missouri 63110, United States
  • Saint Francis Cancer Treatment Center
    Grand Island, Nebraska 68803, United States
  • Hematology and Oncology Associates of Northern New Jersey, P.A.
    Morristown, New Jersey 07962, United States
  • Willamette Valley Cancer Institute and Research Center
    Springfield, Oregon 97477, United States
  • Bon Secours Saint Francis Hospital
    Greenville, South Carolina 29607, United States
  • Greenville Health System Institutional Review Board
    Greenville, South Carolina 29615, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Texas Oncology - Flower Mound
    Denton, Texas 76210, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Oncology and Hematology Associates of Southwest Virginia, Inc.
    Roanoke, Virginia 24014, United States
  • Virginia Mason Clinical Research
    Seattle, Washington 98101, United States
  • UW Cancer Center at ProHealth Care
    Waukesha, Wisconsin 53188, United States
  • FN Brno
    Brno, 625 00, Czechia
  • Fakultni Nemocnice Hradec Kralove
    Hradec Králové, 500 05, Czechia
  • Fakultní nemocnice Královské Vinohrady
    Praha, 100, Czechia
  • Centre Hospitalier Regional Universitaire (CHRU) Brest - Hopital Morvan
    Brest, France
  • CHU Côte de Nacre - Caen
    Caen, France
  • Centre Hospitalier des Oudairies
    La Roche-sur-Yon, France
  • Centre Hospitalier du Mans
    Le Rocher, 72000, France
  • CHR Metz
    Metz, France
  • Centre Hospitalier Universitaire de Nantes (CHU Nantes) - Hotel Dieu
    Nantes, France
  • Centre Hospitalier de Perpignan
    Perpignan, France
  • Centre Hospitalier Universitaire (CHU) de Poitier- Hopital de la Miletrie - Hopital Jean Bernard
    Poitiers, France
  • Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou
    Rennes, France
  • Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi
    Bologna, Italy
  • Azienda Ospedaliera Spedali Civili di Brescia
    Brescia, Italy
  • IRCSS Policlinico San Matteo
    Pavia, Italy
  • Azienda Policlinico Umberto I di Roma
    Roma, 00161, Italy
  • IRCCS Ospedale Casa Sollievo della Sofferenza
    San Giovanni Rotondo, Italy
  • A.O Ospadale Di Circolo E Fondazione Macchi
    Varese, Italy
  • Uniwersyteckie Centrum Kliniczne
    Gdańsk, 80-952, Poland
  • Wojewódzki Szpital Specjalistyczny
    Łódź, 93-510, Poland
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Spain
  • Hospital Universitario Puerta de Hierro
    Majadahonda, Spain
  • Hospital Universitario La Fe
    Valencia, Spain
  • Hospital Clinico Universitario Lozano Blesa de Zaragoza
    Zaragoza, Spain
  • University Hospital's Birmingham NHS Foundation trust-Queen Elizabeth Hospital
    Birmingham, B15 2GW, United Kingdom
  • Liverpool and Broadgreen Hospital
    Liverpool, United Kingdom
  • Maidstone and Tunbridge Wells NHS Trust
    Maidstone, United Kingdom
  • Christie Hospital NHS Foundation Trust
    Manchester, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2015, a primary completion of Sep 2017 and a completion of Sep 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2018, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2015
First posted
Nov 1, 2015
Start
Oct 2015
Primary completionActual
Sep 2017
CompletionActual
Sep 2017
Results first posted
Oct 16, 2018
Last update
Oct 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02594163
Lead sponsor
Seagen Inc.
Responsible party
Sponsor
First posted
Nov 1, 2015
Start date
Oct 2015
Primary completion
Sep 2017
Completion
Sep 2017
Results posted
Oct 16, 2018
Last update
Oct 16, 2018

Study contacts

Thomas Manley, MD
study director · Seagen Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brentuximab Vedotin

Start the discussion